SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications

NCT ID: NCT04327609

Last Updated: 2025-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-10

Study Completion Date

2025-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective multi-center single-blinded randomized controlled trial (RCT) investigating the safety and feasibility of the SELUTION SLR™ (Sustained Limus Release) 018 drug eluting balloon (DEB) for the treatment of failed AV fistula in renal dialysis patients. Patients will be randomised to either SELUTION SLR or POBA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AV Fistula

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SELUTION SLR™ DEB

Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.

Group Type EXPERIMENTAL

SELUTION SLR™ DEB

Intervention Type DEVICE

Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.

Control Treatment

POBA

Group Type ACTIVE_COMPARATOR

Control Arm

Intervention Type DEVICE

The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SELUTION SLR™ DEB

Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.

Intervention Type DEVICE

Control Arm

The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-90 years
* Patient is able and willing to provide written informed consent
* A Dialysis Access that has performed at least 1 successful dialysis session
* Stenosis \>50% at the outflow vein (by visual estimation) with clinical circuit dysfunction
* Lesion of ≤7mm in diameter
* Lesion of up to the 70mm in length

Exclusion Criteria

* Life expectancy \<1year
* Lower extremity AVG
* Infected AVG
* Uncontrolled systemic infection
* Aneurysm or pseudoaneurysm in proposed target lesion
* Presence of previous CS or BMS
* ≥2 lesions present within the circuit
* Unable to perform protocol prescribed pre-dilation of the lesion
* Patient is female and is pregnant, or planning to become pregnant during the course of the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.A. Med Alliance S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Athens

Athens, , Greece

Site Status

University of Patras

Pátrai, , Greece

Site Status

Singapore General Hospital LTD

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SEL-001-2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.